ARTICLE | Emerging Company Profile

64x Bio’s iterative solutions to vector manufacturing pain points

The Harvard spinout’s $55 million A round will fuel partnerships that hone its cell line engineering platform

January 22, 2022 1:54 AM UTC

64x Bio aims to break bottlenecks in viral vector manufacturing with an iterative barcoding- and modeling-based approach to cell line engineering. The Harvard spinout is starting with customized ways to boost the amount of vector produced per cell, but could expand to off-the-shelf solutions and additional approaches focused on vector quality.

Incorporated as  64-X Inc., the company was established to address the mismatch between viral vector manufacturing need and capacity, particularly for gene therapies, said co-founder and CEO Lex Rovner. Other applications on the company’s list include viral vector vaccines and oncolytic viruses...